What is your preferred 3rd line therapy for patients with metastatic sarcomatoid RCC?   

For patients who have progressed on first line checkpoint inhibitor (e.g. Nivo/Ipi) and second line TKI (e.g. Cabozantinib) 



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution